Pro-Dex, Inc. Announces Fiscal 2022 Fourth Quarter And Full-Year Results

Rhea-AI Summary

Pro-Dex, Inc. (NasdaqCM:PDEX) reported its fiscal 2022 fourth quarter and full-year results on August 25, 2022, showing a 34% increase in quarterly net sales to $12.6 million. Annual net sales rose 11% to $42.0 million, driven mainly by orthopedic device sales. However, gross profit decreased 3% year-over-year to $13.1 million, while net income for the year was $3.9 million, down from $5.8 million. Operating expenses decreased 12% due to reduced R&D costs. Supply chain disruptions were noted, but the company remains optimistic about future growth.

Positive

• 34% increase in quarterly net sales to $12.6 million.
• 11% increase in annual net sales to $42.0 million.
• 12% decrease in operating expenses to $8.0 million.

Negative

• Gross profit decreased 3% to $13.1 million.
• Net income fell to $3.9 million from $5.8 million.

IRVINE, CA / ACCESSWIRE / August 25, 2022 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2022 fourth quarter and full-year ended June 30, 2022.

Quarter Ended June 30, 2022

Net sales for the three months ended June 30, 2022 increased $3.2 million, or34%, to $12.6 million from $9.4 million for the three months ended June 30, 2021, due primarily to increased medical device sales and repair revenue. Grossprofit for the threemonths ended June 30, 2022 increased $0.3 million, or 10%, to $3.4 million from $3.1 million for the same period in 2021. Although gross profit increased, our gross margin fell from 33% for the three months ended June 30, 2021 to 27% for the three months ended June 30, 2022, due to continued price increases in many of our purchased components oftentimes out pacing our ability to pass along these increases to our customers.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2022 decreased 11% to $2.3 million from $2.5 million in the prior year's corresponding quarter, due primarily to decreased expenditures of $474,000 in research and development costs as much of our engineering efforts shifted to billable customer contracts in the current fiscal year.

Net income for the quarter ended June 30, 2022 increased by $0.6 million to $1.4 million, or $0.38 per diluted share, compared to $0.8 million, or $0.20 per diluted share, in the corresponding quarter in 2021.

Year Ended June 30, 2022

Net sales for the fiscal year ended June 30, 2022 increased $4.0 million, or 11%, to $42.0 million from $38.0 million for the fiscal year ended June 30, 2021, due primarily to increases in medical device revenues and repair revenues. Specifically, we generated an increase in sales of $3.8 million in fiscal 2022 over fiscal 2021 due to the orthopedic device we sell to our largest customer, in part due to fulfilling orders for the launch of their next generation handpiece.

Grossprofit for the fiscal yearended June 30, 2022 decreased $0.4 million, or 3%, to $13.1 million compared to $13.6 million for fiscal 2021, due to increased cost of sales.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2022 decreased 12% to $8.0 million from $9.1 million in the prior fiscal year. Of the total decrease in operating expenses, $1.4 million relates to a decrease in research and development costs from fiscal 2021 to fiscal 2022 resulting from a shift in engineering efforts from internally developed products to billable customer projects.

Net income for the fiscal year ended June 30, 2022 was $3.9 million, or $1.02 per diluted share, compared to $5.8 million, or $1.48 per diluted share, for fiscal 2021.

Although we have released our earnings prior to our Annual Report on Form 10-K with the Securities and Exchange Commission, we are able to do this because we are a non-accelerated filer and as a result have more time to do so at fiscal year-end. During our quarterly reporting periods, we anticipate that our earnings releases will continue to be released at the same time as our Form 10-Q's are filed with the Securities and Exchange Commission. We anticipate filing our Form 10-K with the Securities and Exchange Commission on September 8, 2022.

Guidance

Pro-Dex typically does not provide sales, earnings, or other guidance, and while the COVID-19 pandemic did not materially adversely affect our financial results in our fiscal year ended June 30, 2022, we did experience disruptions in our supply chain in the form of delayed shipments, longer lead times, and higher prices, much of which our suppliers indicate have been caused by the pandemic. If any of these conditions persist or are exacerbated in the future, we could be negatively impacted. We have and continue to implement plans and processes to mitigate these challenges that many manufacturers similarly face. Our prospects remain positive with additional capacity forthcoming to allow for continued sales growth through our aggressive product development efforts.

CEO Comments

"We are very pleased with our continued year-over-year sales growth, especially given the challenging environment we faced related to sourcing components this fiscal year, as well as the progress we have made in our validation efforts at our new building." said the Company's President and Chief Executive Officer Richard L. ("Rick") Van Kirk. "With our new building and additional capacity coming online this year, combined with our focus on new business development and technology, we are excited about the continued growth we expect to see in the next fiscal year and beyond."

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth and strategies may include "forward-looking statements" within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance (including, but not limited to, the potential future impact of the COVID-19 pandemic, the Company's ability to mitigate supply chain issues, and prospects for future growth) as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business risks of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)

		June 30,
		2022				2021
ASSETS
Current assets:
Cash and cash equivalents		$	849			$	3,721
Investments			755				1,295
Accounts receivable, net of allowance for doubtful accounts of $0 and $2 at June 30, 2022 and 2021, respectively			15,384				10,933
Deferred costs			710				193
Inventory			12,678				8,437
Prepaid expenses and other current assets			790				434
Total current assets			31,166				25,013
Land and building, net			6,343				6,437
Equipment and improvements, net			4,833				3,845
Right of use asset, net			2,248				2,605
Intangibles, net			118				186
Deferred income taxes, net			797				463
Investments			1,779				1,704
Other assets			42				67
Total assets		$	47,326			$	40,320
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	3,761			$	2,288
Accrued liabilities			2,751				2,198
Deferred revenue			1,013				150
Notes payable			3,285				1,236
Total current liabilities			10,810				5,872
Non-current liabilities:
Lease liability, net of current portion			2,054				2,432
Income taxes payable			544				397
Notes payable, net of current portion			10,250				11,535
Total non-current liabilities			12,848				14,364
Total liabilities			23,658				20,236
Commitments and Contingencies:
Shareholders' equity:
Common stock, no par value, 50,000,000 shares authorized; 3,596,131 and 3,645,660 shares issued and outstanding at June 30, 2022 and 2021, respectively			7,682				7,953
Retained earnings			15,986				12,131
Total shareholders' equity			23,668				20,084
Total liabilities and shareholders' equity		$	47,326			$	40,320

PRO-DEX, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS
(In thousands, except per share data)

		Three Months Ended June 30, (Unaudited)								Years Ended June 30,
		2022				2021				2022				2021
Net sales		$	12,615			$	9,435			$	42,041			$	38,029
Cost of sales			9,173				6,316				28,909				24,454
Gross profit			3,442				3,119				13,132				13,575
Operating expenses:
Selling expenses			12				175				91				590
General and administrative expenses			1,501				1,154				4,903				4,076
Loss on disposal of equipment			21				-				35				-
Research and development costs			726				1,200				2,980				4,384
Total operating expenses			2,260				2,529				8,009				9,050
Operating profit			1,182				590				5,123				4,525
Interest expense			(115	)			(121	)			(464	)			(352	)
Unrealized gain (loss) on marketable equity investments			370				(94	)			(57	)			1,371
Gain on sale of investments			28				533				28				1,327
Interest and dividend income			26				23				76				126
Income before income taxes			1,491				931				4,706				6,997
Income tax expense			86				173				851				1,176
Net income		$	1,405			$	758			$	3,855			$	5,821
Basic & Diluted income per share:
Basic net income per share		$	0.39			$	0.21			$	1.06			$	1.53
Diluted net income per share		$	0.38			$	0.20			$	1.02			$	1.48
Weighted average shares outstanding:
Basic			3,608,610				3,656,052				3,635,894				3,796,516
Diluted			3,731,419				3,796,056				3,763,345				3,936,194

PRO-DEX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

		Years Ended June 30,
		2022				2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	3,855			$	5,821
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization			726				686
Unrealized (gain) loss on marketable equity investments			57				(1,371	)
Gain on sale of investments			(28	)			(1,327	)
Impairment of long-lived assets			84				-
Non-cash lease expense			13				26
Gain on sale or disposal of equipment			35				-
Amortization of loan fees			9				49
Share-based compensation			1,275				901
Deferred income taxes			(334	)			(181	)
Bad debt expense (recovery)			(2	)			5
Changes in operating assets and liabilities:
Accounts receivable			(4,449	)			(5,783	)
Deferred costs			(517	)			(38	)
Inventory			(4,241	)			(199	)
Prepaid expenses and other assets			(331	)			(314	)
Accounts payable and accrued expenses			1,991				105
Deferred revenue			863				(50	)
Income taxes payable			147				(408	)
Net cash used in operating activities			(847	)			(2,078	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment and improvements			(1,638	)			(1,769	)
Purchase of land and building			-				(6,499	)
Proceeds from sale of investments			770				4,596
Increase in intangibles			(33	)			(38	)
Purchase of investments			(334	)			-
Net cash used in investing activities			(1,235	)			(3,710	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable			(1,244	)			(351	)
Borrowing from Minnesota Bank & Trust, net of loan origination fees			2,000				9,139
Repurchases of common stock			(1,606	)			(5,537	)
Payments of employee taxes on net issuance of common stock			-				(259	)
Proceeds from exercise of stock options and ESPP contributions			60				96
Net cash provided by (used in) financing activities			(790	)			3,088
Net decrease in cash and cash equivalents			(2,872	)			(2,700	)
Cash and cash equivalents, beginning of year			3,721				6,421
Cash and cash equivalents, end of year		$	849			$	3,721

SOURCE: Pro-Dex, Inc.

View source version on accesswire.com:
https://www.accesswire.com/713327/Pro-Dex-Inc-Announces-Fiscal-2022-Fourth-Quarter-And-Full-Year-Results

FAQ

What were Pro-Dex's Q4 financial results for June 30, 2022?

Pro-Dex reported a 34% increase in net sales to $12.6 million and a net income of $1.4 million for the quarter.

How did Pro-Dex's annual sales perform for fiscal year 2022?

Pro-Dex achieved an 11% increase in annual sales to $42.0 million for fiscal year 2022.

What were the operating expenses for Pro-Dex in fiscal year 2022?

Operating expenses for Pro-Dex decreased 12% to $8.0 million for fiscal year 2022.

What challenges did Pro-Dex face in fiscal year 2022?

Pro-Dex experienced supply chain disruptions leading to delayed shipments and increased costs.

What is Pro-Dex's outlook for future growth?

Pro-Dex remains optimistic about growth, citing new capacity and ongoing product development efforts.